Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
05 January 2022 - 11:30PM
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”)
today announced that it will present the Company’s vision and its
intended future development pathways at the 40th Annual J.P. Morgan
Healthcare Conference on Monday, January 10, 2022, at approximately
3:45 PM EST. Robert W. Duggan, Chairman and Chief Executive
Officer, and Dr. Maky Zanganeh, Chief Operating Officer and a
member of Summit’s Board of Directors, will provide details
regarding Summit’s commitments towards its future research and
clinical development goals, in addition to its current product
pipeline.
The presentation will be available the following
day on the home page of our website:
https://www.summittxinc.com.
About Summit Therapeutics
The overriding objective of Summit Therapeutics
is to create value for patients, hospital caregivers, and
community-based healthcare providers, as well as healthcare payers
around the world. We seek to create value by developing drugs with
high therapeutic efficacy - curing the cause or effect of the
patient's condition with minimal or zero disease recurrence or
antimicrobial resistance, for the longest extent possible - and
minimizing the trauma caused to the patient and healthcare
ecosystem by minimizing serious side effects, disease recurrence,
and inaccessibility to our treatments as a result of financial or
other barriers. Summit Therapeutics, empowered by its Discuva
Platform, the Company’s innovative antibiotic discovery engine, and
supported by BARDA and CARB-X funding, intends to be the leader in
patient-friendly and paradigm-shifting treatments for infectious
diseases and other significant unmet medical needs while being an
ally to physicians. Our new era, novel mechanism pipeline product
candidates are designed with the goal to become the
patient-friendly, new-era standard of care, by working in harmony
with the human microbiome to treat prospective patients suffering
from infectious diseases, initially focusing on Clostridioides
difficile infection (CDI). Currently, Summit’s lead product
candidate, ridinilazole, is a novel, first-in-class drug engaged in
a global Phase III trial program. Commercialization of ridinilazole
is subject to regulatory approvals. SMT-738, the second candidate
within Summit’s portfolio, is currently in the IND-enabling phase
for the treatment of multidrug resistant infections, specifically
those caused by carbapenem-resistant Enterobacteriaceae (CRE).
For more information, please visit
https://www.summittxinc.com and follow us on Twitter
@summitplc. For more information on the Company’s Discuva
Platform, please visit
https://www.summittxinc.com/our-science/discuva-platform.
Contact Summit Investor Relations:
Dave GancarzHead of Stakeholder Relations &
Corporate Strategydavid.gancarz@summitplc.com
General Inquiries:
investors@summitplc.com
Summit Forward-looking Statements
Any statements in this press release about the
Company’s future expectations, plans and prospects, including but
not limited to, statements about the clinical and preclinical
development of the Company’s product candidates, the therapeutic
potential of the Company’s product candidates, the potential
commercialization of the Company’s product candidates, the timing
of initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing
approvals, the impact of the COVID-19 pandemic on the Company’s
operations and clinical trials and other statements containing the
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "would," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: the uncertainties inherent in the
initiation of future clinical trials, availability and timing of
data from ongoing and future clinical trials and the results of
such trials, global public health crises, including the coronavirus
COVID-19 outbreak, that may affect timing and status of our
clinical trials and operations, whether preliminary results from a
clinical trial will be predictive of the final results of that
trial or whether results of early clinical trials or preclinical
studies will be indicative of the results of later clinical trials,
expectations for regulatory approvals, laws and regulations
affecting government contracts and funding awards, availability of
funding sufficient for the Company’s foreseeable and unforeseeable
operating expenses and capital expenditure requirements and other
factors discussed in the "Risk Factors" section of filings that the
Company makes with the Securities and Exchange Commission.
Any change to our ongoing trials could cause delays, affect our
future expenses, and add uncertainty to our commercialization
efforts, as well as to affect the likelihood of the successful
completion of clinical development of ridinilazole.
Accordingly, readers should not place undue reliance on
forward-looking statements or information. In addition, any
forward-looking statements included in this press release represent
the Company’s views only as of the date of this release and should
not be relied upon as representing the Company’s views as of any
subsequent date. The Company specifically disclaims any
obligation to update any forward-looking statements included in
this press release.
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024